HighTower Advisors
BCLI

HighTower Advisors’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

HighTower Advisors’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-683
Closed -$3K – 3635
2023
Q4 		$3K Sell
683
-15
-2% -$45 ﹤0.01% 3490
2023
Q3 		$2K Buy
+698
New +$15.9K ﹤0.01% 3467
2021
Q2 		– Sell
-701
Closed -$40K – 3165
2021
Q1 		$40K Buy
+701
New +$52.9K ﹤0.01% 2851
2019
Q4 		– Sell
-684
Closed -$40K – 2366
2019
Q3 		$40K Hold
684
– – ﹤0.01% 2237
2019
Q2 		$41K Sell
684
-34
-5% -$1.98K ﹤0.01% 2223
2019
Q1 		$46K Hold
718
– – ﹤0.01% 2124
2018
Q4 		$39K Hold
718
– – ﹤0.01% 2046
2018
Q3 		$41K Hold
718
– – ﹤0.01% 2137
2018
Q2 		$42K Hold
718
– – ﹤0.01% 2074
2018
Q1 		$35K Hold
718
– – ﹤0.01% 2033
2017
Q4 		$42K Buy
718
+34
+5% +$2.03K ﹤0.01% 2115
2017
Q3 		$42K Hold
684
– – ﹤0.01% 2097
2017
Q2 		$43K Sell
684
-34
-5% -$2.1K ﹤0.01% 2039
2017
Q1 		$46K Hold
718
– – ﹤0.01% 1926
2016
Q4 		$27K Hold
718
– – ﹤0.01% 1851
2016
Q3 		$26K Hold
718
– – ﹤0.01% 1814
2016
Q2 		$26K Hold
718
– – ﹤0.01% 1671
2016
Q1 		$29K Buy
+718
New +$26.4K ﹤0.01% 1981
2015
Q2 		– Sell
-818
Closed -$54K – 1573
2015
Q1 		$54K Buy
818
+134
+20% +$8.47K ﹤0.01% 1535
2014
Q4 		$49K Buy
+684
New +$35.9K ﹤0.01% 1506

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

HighTower Advisors's BCLI Position: Q1 2024 in Review

HighTower Advisors sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2024, closing a stake of 683 shares — an estimated $3K sold.

HighTower Advisors first reported a position in BCLI in Q4 2014 and held it in 20 quarters. The position peaked at $54K in Q1 2015. 47 funds tracked by Wall St. Rank hold BCLI as of Q1 2024.

  • HighTower Advisors reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2024 after selling out during the quarter.
  • HighTower Advisors sold 683 BRAINSTORM CELL THERAPUTC shares in Q1 2024, an estimated $3K.
  • HighTower Advisors first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2014 and held it in 20 quarters.
  • HighTower Advisors's BRAINSTORM CELL THERAPUTC position peaked at $54K in Q1 2015.
  • 47 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2024.

Based on HighTower Advisors's 13F filing for Q1 2024, filed 6 May 2024.